Aneta Ścieżyńska

Dr. Aneta Ścieżyńska

Department of Histology and Embryology, Medical University in Warsaw, Warsaw, Mazowieckie, Poland
+1

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AŚAneta Ścieżyńska
Aneta Ścieżyńska
MKMichał Komorowski
Michał Komorowski
MSMarta Soszyńska
Marta Soszyńska
JMJacek Malejczyk
Jacek Malejczyk
Endometriosis is a common gynecological disease defined by the presence of endometrial-like tissue outside the uterus, most frequently on the pelvic viscera and ovaries, which is associated with pelvic pains and infertility. It is an inflammatory disorder with some features of autoimmunity. It is accepted that ectopic endometriotic tissue originates from endometrial cells exfoliated during menstruation and disseminating into the peritoneum by retrograde menstrual blood flow. It is assumed that the survival of endometriotic cells in the peritoneal cavity may be partially due to their abrogated elimination by natural killer (NK) cells. The decrease of NK cell cytotoxic activity in endometriosis is associated with an increased expression of some inhibitory NK cell receptors. It may be also related to the expression of human leukocyte antigen G (HLA-G), a ligand for inhibitory leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1) receptors. The downregulated cytotoxic activity of NK cells may be due to inhibitory cytokines present in the peritoneal milieu of patients with endometriosis. The role of NK cell receptors and their ligands in endometriosis is also confirmed by genetic association studies. Thus, endometriosis may be a subject of immunotherapy by blocking NK cell negative control checkpoints including inhibitory NK cell receptors. Immunotherapies with genetically modified NK cells also cannot be excluded.

13 December 2018 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
AŚAneta Ścieżyńska
Aneta Ścieżyńska
ANAleksandra Nogowska
Aleksandra Nogowska
MSMaria Sikorska
Maria Sikorska
JKJustyna Konys
Justyna Konys
AKAnita Karpińska
Anita Karpińska
JMJacek Malejczyk
Jacek Malejczyk

1 April 2016 in Experimental Eye Research
Verified
Journal Article
Closed access
AŚAneta Ścieżyńska
Aneta Ścieżyńska
DODominika Oziębło
Dominika Oziębło
AAAnna M. Ambroziak
Anna M. Ambroziak
MKMagdalena Korwin
Magdalena Korwin
KSKamil Szulborski
Kamil Szulborski
MOMonika Oldak
Monika Oldak

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MOMonika Oldak
Monika Oldak
EREwelina Ruszkowska
Ewelina Ruszkowska
MUMonika Udziela
Monika Udziela
DODominika Oziębło
Dominika Oziębło
EBEwelina Bińczyk
Ewelina Bińczyk
JSJacek P. Szaflik
Jacek P. Szaflik
Fuchs endothelial corneal dystrophy (FECD) is a common corneal endotheliopathy with a complex and heterogeneous genetic background. Different variants in theTCF4gene have been strongly associated with the development of FECD.TCF4encodes the E2-2 transcription factor but the link between the strong susceptibility locus and disease mechanism remains elusive. Here, we confirm a strong positive association betweenTCF4single nucleotide polymorphism rs613872 and FECD in Polish patients (OR = 12.95, 95% CI: 8.63–19.42,χ2=189.5,p<0.0001). We show thatTCF4expression at the mRNA level in corneal endothelium (n=63) does not differ significantly between individuals with a particularTCF4genotype. It is also not altered in FECD patients as compared to control samples. The data suggest that changes in the transcript level containing constitutiveTCF4exon encoding the amino-terminal part of the protein seem not to contribute to disease pathogenesis. However, considering the strong association ofTCF4allelic variants with FECD, genotyping ofTCF4risk alleles may be important in the clinical practice.

Verified
Journal Article
Open access
PDF file
MRMarcin Radziszewski
Marcin Radziszewski
RGRyszard Galus
Ryszard Galus
KŁKrzysztof Łuszczyński
Krzysztof Łuszczyński
SWSebastian Winiarski
Sebastian Winiarski
DWDariusz Wąsowski
Dariusz Wąsowski
AŚAneta Ścieżyńska
Aneta Ścieżyńska
The receptor for advanced glycation end-products (RAGE), a member of the immunoglobulin superfamily, is expressed in various cell types and mediates cellular responses to a wide range of ligands. The activation of RAGE triggers complex signaling pathways that drive inflammatory, oxidative, and proliferative responses, which are increasingly implicated in the pathogenesis of skin diseases. Despite its well-established roles in conditions such as diabetes, cancer, and chronic inflammation, the contribution of RAGE to skin pathologies remains underexplored. This review synthesizes current findings on RAGE’s involvement in the pathophysiology of skin diseases, including conditions such as psoriasis, atopic dermatitis, and lichen planus, focusing on its roles in inflammatory signaling, tissue remodeling, and skin cancer progression. Additionally, it examines RAGE-modulating treatments investigated in dermatological contexts, highlighting their potential as therapeutic options. Given RAGE’s significance in a variety of skin conditions, further research into its mediated pathways may uncover new opportunities for targeted interventions in skin-specific RAGE signaling.

28 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
AŚAneta Ścieżyńska
Aneta Ścieżyńska
MSMarta Soszyńska
Marta Soszyńska
PSPatrycja Szpak
Patrycja Szpak
NKNatalia Krześniak
Natalia Krześniak
JMJacek Malejczyk
Jacek Malejczyk
IKIlona Kalaszczynska
Ilona Kalaszczynska
Mesenchymal stem cells have generated a great deal of interest due to their potential use in regenerative medicine and tissue engineering. Examples illustrating their therapeutic value across various in vivo models are demonstrated in the literature. However, some clinical trials have not proved their therapeutic efficacy, showing that translation into clinical practice is considerably more difficult and discrepancies in clinical protocols can be a source of failure. Among the critical factors which play an important role in MSCs’ therapeutic efficiency are the method of preservation of the stem cell viability and various characteristics during their storage and transportation from the GMP production facility to the patient’s bedside. The cell storage medium should be considered a key factor stabilizing the environment and greatly influencing cell viability and potency and therefore the effectiveness of advanced therapy medicinal product (ATMP) based on MSCs. In this review, we summarize data from 826 publications concerning the effect of the most frequently used cell preservation solutions on MSC potential as cell-based therapeutic medicinal products.